Literature DB >> 15203746

Immunohistochemistry in gynaecological pathology: a review.

Veli-Matti Marjoniemi1.   

Abstract

This paper reviews some aspects of the application of immunohistochemistry in gynaecological pathology. The use of cytokeratins 7 and 20 are discussed with reference to applications in ovarian pathology, including metastatic disease to the ovaries. Developments in utilising MIB-1 and p16 in cervical squamous and glandular lesions are discussed. Recent assertions regarding the differential diagnosis between endocervical and endometrial carcinomas are also reviewed. Antibodies that may be of use in the diagnosis of uterine mesenchymal and ovarian tumours are highlighted, as are antibodies of use in trophoblastic lesions including the use of p57 in evaluating hydatidiform moles.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15203746     DOI: 10.1080/00313020410001671948

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  4 in total

Review 1.  Aberrant cell cycle regulation in cervical carcinoma.

Authors:  Young Tae Kim; Min Zhao
Journal:  Yonsei Med J       Date:  2005-10-31       Impact factor: 2.759

2.  ELISA test to detect CDKN2A (p16(INK4a)) expression in exfoliative cells: a new screening tool for cervical cancer.

Authors:  Li Ding; Xian-Jin Zou; Jin-E Ao; Ai-Xiang Yao; Lan Cai
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

3.  Primary peritoneal carcinoma presenting as a Sister Mary Joseph's nodule: A case report and review of the literature.

Authors:  Robyn L Schickler; Reem Abdallah; E Clair McClung; Mian M K Shahzad
Journal:  Gynecol Oncol Rep       Date:  2016-05-21

4.  Relevance of immunohistochemical expression of p57kip2 in epithelial ovarian carcinoma- A systematic literature review.

Authors:  Thumuluru Kavitha Madhuri; Anil Tailor; Ben Haagsma; Helen Coley; Simon Butler-Manuel
Journal:  J Ovarian Res       Date:  2012-12-21       Impact factor: 4.234

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.